Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$943 Mln
Revenue (TTM)
$244 Mln
Net Profit (TTM)
$-20 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
39.7
P/B Ratio
1.4
Industry P/E
24.51
EV/EBITDA
6.6
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$--
EPS
$-0.2
Face value
--
Shares outstanding
64,133,900
CFO
€-37.62 Mln
EBITDA
€-105.25 Mln
Net Profit
€-301.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amryt Pharma (AMYT)
| 101.4 | 0.9 | 0.2 | 94.4 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Amryt Pharma (AMYT)
| -32.4 | -23.7 |
|
S&P Small-Cap 600
| -17.4 | 25.3 |
|
BSE Sensex
| 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct... to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland. Read more
CEO & Director
Dr. Joseph A. Wiley
CEO & Director
Dr. Joseph A. Wiley
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Amryt Pharma plc (AMYT) is $14.70 (NASDAQ) as of 21-Apr-2023 09:30 EDT. Amryt Pharma plc (AMYT) has given a return of 94.44% in the last 1 years.
The P/E ratio of Amryt Pharma plc (AMYT) is 39.73 times as on 21-Apr-2023, a 62 premium to its peers’ median range of 24.51 times.
The P/B ratio of Amryt Pharma plc (AMYT) is 1.40 times as on 21-Apr-2023, a 75 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-29.12
|
1.57
|
|
2020
|
-4.33
|
6.85
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Amryt Pharma plc (AMYT) are Rs -- and Rs -- as of 03-Apr-2026.
Amryt Pharma plc (AMYT) has a market capitalisation of $ 943 Mln as on 21-Apr-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Amryt Pharma plc (AMYT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.